Maven Securities’s AnaptysBio ANAB Stock Holding History

Maven Securities’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-28,000	Closed	-$2.77M	–	87
2018 Q3	$2.77M	Buy	+28,000	New	+$2.32M	1.02%	29

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Maven Securities's ANAB Position: Q4 2018 in Review

Maven Securities sold out of AnaptysBio (ANAB) in Q4 2018, closing a stake of 28,000 shares — an estimated $2.77M sold.

Maven Securities first reported a position in ANAB in Q3 2018 and held it in 1 quarter. The position peaked at $2.77M in Q3 2018. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2018.

Maven Securities reported no remaining AnaptysBio position as of Q4 2018 after selling out during the quarter.
Maven Securities sold 28,000 AnaptysBio shares in Q4 2018, an estimated $2.77M.
Maven Securities first reported a position in AnaptysBio in Q3 2018 and held it in 1 quarter.
Maven Securities's AnaptysBio position peaked at $2.77M in Q3 2018.
121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2018.

Based on Maven Securities's 13F filing for Q4 2018, filed 14 Feb 2019.